Therovia Specification

Home / Therovia / Therovia Specification

Therovia

Because the World Has More Treatment Options.

Specification

Therovia is an AGPL-3.0+ open source specification for a global AI-powered treatment intelligence system designed to discover, organize, compare, verify, and continuously update information about treatments and potential cures for diseases worldwide.

Therovia is designed to search beyond the treatment options approved by a patient’s local government or regulatory authority. It can identify approved treatments, off-label treatments, investigational therapies, clinical trials, compassionate-use programs, expanded-access pathways, Right to Try pathways, foreign-approved treatments, traditional medicines, experimental approaches, emerging therapies, and other documented treatment possibilities.

Therovia does not equate discovery with effectiveness, regulatory approval, safety, or availability. Every treatment is classified according to its evidence, regulatory status, safety profile, geographic availability, and applicable access pathway.

Mission

Therovia exists to make the world’s treatment knowledge discoverable.

A treatment should not disappear from consideration simply because it is:

Developed in another country
Not approved in the patient’s country
Approved for another indication
Still under investigation
Available only through a clinical trial
Available through compassionate use
Available through expanded access
Potentially accessible through a Right to Try pathway
Considered traditional or complementary medicine
Newly discovered
Poorly indexed
Experimental
Supported by preliminary evidence

Therovia shall present these possibilities with clear evidence and status classifications rather than treating them as equivalent medical options.

Design Principles

Therovia shall follow these principles:

Global treatment discovery
Evidence transparency
Source provenance
Regulatory neutrality
Patient-centered information access
Jurisdiction-aware access information
Human clinical oversight
Continuous research
Explicit uncertainty
Transparent AI reasoning
Modular architecture
Open source interoperability
Vendor neutrality
Auditable data
Privacy-conscious design
No unsupported claims of cures
No assumption that government approval equals medical effectiveness
No assumption that lack of government approval equals ineffectiveness

Core Modules

Global Treatment Database

The Global Treatment Database maintains structured records for treatments and treatment approaches identified through authoritative, academic, clinical, historical, traditional, and other appropriately sourced information.

Treatment records may include:

Treatment name
Generic name
Brand name
Active ingredients
Biological products
Medical devices
Procedures
Surgical interventions
Radiation treatments
Cellular therapies
Gene therapies
Immunotherapies
Vaccines
Metabolic interventions
Dietary interventions
Traditional medicines
Herbal medicines
Complementary therapies
Integrative therapies
Experimental therapies
Treatment combinations
Treatment protocols
Treatment sequences

Each record shall maintain its source, jurisdiction, evidence classification, regulatory status, availability, safety information, and verification history.

Disease Knowledge Graph

The Disease Knowledge Graph connects diseases with their known characteristics and treatment relationships.

The module shall support:

Diseases
Disease subtypes
Stages
Severity
Molecular characteristics
Genetic characteristics
Biomarkers
Mutations
Symptoms
Comorbidities
Treatment relationships
Treatment responses
Resistance patterns
Disease progression
Recurrence
Remission
Potentially curative approaches

The knowledge graph shall allow the AI to identify treatments relevant to specific disease characteristics rather than relying exclusively on broad disease names.

Evidence Engine

The Evidence Engine evaluates and classifies the available evidence for each treatment.

Evidence classifications may include:

Regulatory approval
Clinical guideline recommendation
Randomized controlled trial
Prospective clinical study
Retrospective clinical study
Systematic review
Meta-analysis
Observational study
Case series
Case report
Preclinical evidence
Laboratory evidence
Animal research
Mechanistic evidence
Historical evidence
Traditional-use evidence
Expert opinion
Anecdotal evidence
Unsupported claim

The system shall preserve conflicting evidence and shall not automatically interpret a positive result as proof of effectiveness.

Source Provenance Engine

The Source Provenance Engine records where treatment information originated.

Records should include:

Source
Source type
Author
Organization
Publication date
Jurisdiction
Publication identifier
Source URL
Evidence type
Extraction date
Verification date
Source reliability
Conflicting sources
Retraction status
AI interpretation
Confidence level

Users shall be able to trace significant treatment claims back to their underlying sources.

Regulatory Status Engine

The Regulatory Status Engine records treatment approval and regulatory status independently for each jurisdiction.

A treatment may simultaneously be:

Approved in one country
Investigational in another
Unavailable in another
Approved for another indication
Available through a clinical trial
Available through compassionate use
Available through expanded access

The system shall never treat lack of approval in a particular jurisdiction as evidence that the treatment does not exist.

Jurisdiction Engine

The Jurisdiction Engine maintains information about country-specific treatment regulations and access pathways.

It may track:

Regulatory authorities
Approval requirements
Clinical trial access
Compassionate-use rules
Expanded-access rules
Experimental treatment rules
Special access programs
Physician requirements
Hospital requirements
Manufacturer requirements
Importation requirements
Patient eligibility
Documentation requirements
Emergency access provisions

Jurisdictional information shall be time-stamped and continuously updated because laws and policies change.

Treatment Matching Engine

The Treatment Matching Engine compares available treatment information against user-provided disease information.

Potential matching attributes include:

Diagnosis
Disease subtype
Stage
Biomarkers
Mutations
Prior treatments
Treatment responses
Treatment failures
Medications
Allergies
Contraindications
Patient characteristics
Treatment goals
Geographic location
Applicable jurisdiction

The engine shall identify potentially relevant treatment information without representing the result as an autonomous medical prescription.

Treatment Comparison Engine

The Treatment Comparison Engine allows users to compare treatment options using structured attributes.

Comparison factors may include:

Mechanism
Disease indication
Disease subtype
Evidence quality
Clinical outcomes
Response rates
Remission data
Survival data
Adverse effects
Contraindications
Regulatory status
Countries of approval
Countries of availability
Clinical trial availability
Access pathways
Treatment duration
Treatment location
Manufacturer
Physician requirements
Known access barriers
Cost information where reliably available

The system shall display the underlying factors rather than reducing treatment decisions to an unexplained single score.

Safety Engine

The Safety Engine identifies and classifies known and suspected treatment risks.

The system shall track:

Adverse effects
Serious adverse effects
Contraindications
Drug interactions
Treatment interactions
Organ-specific risks
Pregnancy-related risks
Age-related risks
Genetic risks
Biomarker-specific risks
Dosing uncertainty
Manufacturing concerns
Contamination concerns
Quality-control concerns
Counterfeit-product risks
Treatment withdrawals
Safety warnings

Experimental, traditional, natural, or foreign-approved status shall never be interpreted as proof of safety.

Clinical Trial Engine

The Clinical Trial Engine identifies clinical trials associated with diseases and treatments.

The module shall track:

Trial title
Trial identifier
Sponsor
Treatment
Disease
Eligibility requirements
Trial phase
Recruitment status
Locations
Contact information
Study dates
Primary outcomes
Secondary outcomes
Published results
Trial history

The system shall distinguish between active recruitment, completed studies, terminated studies, suspended studies, and studies with unavailable recruitment information.

Access Pathway Engine

The Access Pathway Engine identifies potential legal and clinical pathways through which a patient may obtain an investigational or otherwise restricted treatment.

Pathways may include:

Right to Try
Expanded access
Compassionate use
Named-patient access
Individual patient access
Emergency access
Special access programs
Clinical trials
Physician-requested access
Manufacturer access programs
Hospital-based investigational protocols
Jurisdiction-specific experimental treatment pathways

The system shall distinguish between:

Existence of a pathway
Potential eligibility
Confirmed eligibility
Application requirements
Physician requirements
Manufacturer participation
Regulatory requirements
Institutional requirements
Actual treatment availability

The system shall never claim that a patient has a legal right to obtain a treatment unless that conclusion is supported by applicable law and current authoritative information.

Right to Try Module

The Right to Try module shall identify applicable Right to Try laws and eligibility requirements where such laws exist.

The module shall:

Identify the relevant jurisdiction
Identify applicable eligibility criteria
Identify qualifying investigational treatments
Identify relevant treatment developers
Identify required physician participation
Identify required patient documentation
Identify applicable regulatory requirements
Identify known limitations
Identify whether manufacturer participation is required
Display the date on which the legal information was verified

Right to Try shall not be treated as a universal international access mechanism.

Expanded Access Module

The Expanded Access Module shall identify expanded-access and compassionate-use mechanisms applicable to investigational treatments.

The module shall identify:

Eligibility requirements
Treatment eligibility
Physician requirements
Manufacturer participation
Regulatory applications
Institutional requirements
Emergency procedures
Documentation
Jurisdiction
Current status

Cure Discovery Engine

The Cure Discovery Engine distinguishes between different meanings of treatment success.

Classifications may include:

Documented cure
Durable remission
Long-term disease control
Partial response
Temporary response
Symptom management
Preventive intervention
Potentially curative treatment
Experimental curative approach
Proposed cure
Anecdotal cure claim
Unsupported cure claim

The system shall not classify a treatment as a cure merely because a source or organization uses the word “cure.”

AI Research Agent

The AI Research Agent continuously searches for new information.

It shall identify:

New treatments
New clinical trials
Trial results
Regulatory approvals
Regulatory withdrawals
Safety warnings
Expanded-access programs
Compassionate-use programs
New treatment guidelines
New biomarkers
New treatment combinations
Emerging therapies
New research
New evidence concerning existing treatments

The system shall maintain historical changes rather than silently replacing previous records.

Treatment Claim Verification Engine

The Treatment Claim Verification Engine evaluates claims made about treatments.

It shall identify potential:

Unsupported cure claims
Fraudulent treatment claims
Fabricated studies
Fabricated clinical trials
Retracted studies
Misleading marketing
Conflicts of interest
Duplicate publications
Outdated treatment information
Contradictory evidence
Treatments withdrawn for safety reasons

The system shall distinguish between the existence of a claim and evidence supporting that claim.

Global Access Map

The Global Access Map provides geographic information about treatment availability.

The map may display:

Countries where treatment is approved
Countries where treatment is investigational
Clinical trial locations
Compassionate-use programs
Expanded-access programs
Participating manufacturers
Treatment centers
Specialized physicians
Access requirements
Geographic restrictions

Patient Autonomy Engine

The Patient Autonomy Engine provides users with information needed to investigate treatment possibilities and discuss them with qualified healthcare professionals.

The system shall allow users to:

Search treatments
Compare treatments
Review evidence
Review safety information
Explore international treatment options
Explore clinical trials
Explore access pathways
Identify questions to discuss with clinicians
Track treatments under consideration
Review changes in evidence

The system shall not replace professional diagnosis, prescribing, or clinical judgment.

Human Verification Engine

The Human Verification Engine provides workflows for review of high-risk or disputed treatment information.

Potential reviewers include:

Physicians
Pharmacists
Clinical researchers
Regulatory specialists
Medical librarians
Medical subject-matter experts

Human review shall be auditable and shall preserve the distinction between AI-generated analysis and human verification.

Data Freshness Engine

The Data Freshness Engine monitors the age and reliability of time-sensitive information.

Priority rechecks shall include:

Regulatory status
Clinical trial recruitment
Treatment availability
Safety warnings
Manufacturer access programs
Compassionate-use programs
Expanded-access programs
Treatment guidelines
Legal access requirements

Each record shall maintain a last-verified date.

Audit and Verification Engine

The Audit and Verification Engine maintains a complete history of important changes.

The system shall track:

Record creation
Record modification
Source changes
Evidence changes
Regulatory changes
Safety changes
Treatment classification changes
Human reviews
AI-generated assessments
Corrections
Retractions
Conflicting evidence

Users shall be able to determine how and why an important treatment record changed.

Optional Plugin Modules

Therovia shall support optional plugins that extend the core treatment intelligence system without requiring every deployment to install every specialized capability.

Cancer Intelligence Plugin

Provides specialized treatment discovery for:

Solid tumors
Hematological cancers
Rare cancers
Molecular cancer subtypes
Stage-specific treatment
Biomarker-specific treatment
Experimental oncology
Cancer clinical trials
Cancer treatment combinations

Rare Disease Intelligence Plugin

Provides specialized discovery for rare diseases, orphan treatments, rare disease clinical trials, specialty treatment centers, and international treatment programs.

Genetic Disease Intelligence Plugin

Provides treatment discovery based on genetic mutations, inherited diseases, gene-specific interventions, gene therapies, and precision medicine.

Precision Medicine Plugin

Provides biomarker-driven treatment matching and molecular treatment discovery.

Drug Repurposing Plugin

Identifies existing drugs being investigated or used for diseases beyond their original indications.

The plugin shall clearly distinguish approved indications from off-label and investigational uses.

Traditional Medicine Plugin

Provides structured information about traditional, complementary, and integrative medicine.

Traditional use shall remain distinct from clinical evidence.

Indigenous Knowledge Plugin

Provides support for appropriately sourced indigenous treatment knowledge while respecting cultural attribution, intellectual property, community rights, access restrictions, and applicable ethical requirements.

Medical Travel Plugin

Identifies international treatment centers, specialty hospitals, physicians, treatment programs, and jurisdiction-specific access information.

The plugin shall not represent geographic availability as a recommendation of treatment.

Treatment Cost Intelligence Plugin

Tracks publicly available treatment cost information, including:

Medication costs
Treatment costs
Clinical trial costs
Travel-related treatment costs
Access program costs
Insurance information where available

Cost information shall include its source and date.

Pharmaceutical Pipeline Plugin

Tracks investigational treatments and development pipelines maintained by pharmaceutical and biotechnology organizations.

Gene Therapy Plugin

Provides specialized discovery for gene replacement, gene editing, gene silencing, and other gene-based therapies.

Cell Therapy Plugin

Provides specialized discovery for cellular therapies, stem-cell-based interventions, immune-cell therapies, and related investigational approaches.

Medical Device Plugin

Provides treatment intelligence for medical devices, diagnostic technologies, implantable technologies, therapeutic devices, and investigational devices.

Infectious Disease Plugin

Provides specialized treatment discovery for infectious diseases, antimicrobial therapies, antiviral therapies, antifungal therapies, antiparasitic therapies, vaccines, and emerging infectious diseases.

Neurological Disease Plugin

Provides specialized treatment discovery for neurological and neurodegenerative diseases.

Cardiovascular Disease Plugin

Provides specialized treatment discovery for cardiovascular diseases and cardiovascular interventions.

Autoimmune Disease Plugin

Provides specialized treatment discovery for autoimmune and inflammatory diseases.

Pediatric Treatment Plugin

Provides specialized treatment intelligence for pediatric diseases while applying age-specific safety and regulatory requirements.

Veterinary Medicine Plugin

Provides a separate treatment intelligence layer for veterinary diseases and animal medicine.

Global Source Integration

Therovia should integrate information from a broad range of sources, including:

Government regulatory agencies
National health authorities
International health organizations
Clinical trial registries
Academic publications
Medical journals
Universities
Hospitals
Research institutions
Pharmaceutical companies
Biotechnology companies
Medical device companies
Treatment guidelines
Systematic reviews
Meta-analyses
Case reports
Historical medical literature
Traditional medicine sources
Pharmacopoeias
Patents
Preprints
Conference publications
Publicly documented experimental programs

Sources shall be classified by type and reliability.

Global Regulatory Independence

Therovia shall not restrict treatment discovery to a single regulatory authority.

The system shall maintain independent regulatory records for different jurisdictions.

Regulatory approval shall be treated as one attribute of a treatment rather than the sole determinant of whether the treatment is included.

Evidence and Regulatory Separation

Therovia shall maintain separate classifications for:

Evidence
Safety
Regulatory approval
Availability
Legal access
Clinical recommendation
Patient compatibility

A treatment may have substantial evidence without local approval.

A treatment may have regulatory approval without being appropriate for a particular disease subtype.

A treatment may be legally accessible without having strong evidence.

The system shall preserve these distinctions.

Safety and Medical Responsibility

Therovia is an information and treatment discovery system and shall not function as an autonomous prescribing authority.

The system shall not:

Fabricate treatments
Fabricate clinical trials
Fabricate regulatory approvals
Fabricate physicians
Fabricate treatment centers
Fabricate access programs
Present experimental treatments as proven cures
Hide known safety concerns
Present anecdotes as clinical evidence
Present foreign approval as proof of local legality
Present Right to Try as universally applicable
Provide false certainty about treatment outcomes

High-risk treatment information shall be clearly identified and supported by source provenance.

Privacy

Patient-specific treatment matching shall follow privacy-conscious principles.

The system should minimize collection of personally identifiable information and should support local processing where technically feasible.

Patient information shall not be used for unrelated purposes without appropriate authorization.

Interoperability

Therovia shall support interoperable data exchange with:

Medical databases
Clinical trial registries
Regulatory databases
Research repositories
Treatment centers
Pharmaceutical databases
Patient applications
Physician applications
Health information systems

The architecture shall avoid dependency on a single vendor, database provider, government, pharmaceutical company, or AI provider.

API

Therovia should provide APIs for:

Disease discovery
Treatment discovery
Evidence retrieval
Regulatory status
Treatment comparison
Clinical trials
Access pathways
Jurisdiction information
Source provenance
Treatment safety
Geographic availability
AI research results

API responses should preserve provenance and treatment classifications.

AI Transparency

AI-generated information shall be distinguishable from source information.

The system should expose:

Sources consulted
Evidence supporting conclusions
Confidence
Conflicting evidence
Data freshness
Regulatory status
AI-generated interpretation
Human verification status

The AI shall not conceal uncertainty when evidence is incomplete or contradictory.

Treatment Opportunity Analysis

Therovia may calculate treatment opportunity profiles using separately displayed factors including:

Evidence
Potential benefit
Safety
Treatment compatibility
Availability
Regulatory status
Access pathway
Geographic accessibility
Clinical trial availability
Treatment urgency

No single composite score shall replace the underlying information.

International Treatment Discovery

Therovia shall allow users to discover treatment options from outside their home country.

International discovery may include:

Foreign-approved treatments
Clinical trials
Investigational therapies
Specialty treatment centers
Compassionate-use programs
Expanded-access programs
Named-patient programs
Special access programs
Experimental treatment programs

International availability shall not be interpreted as legal permission to import or receive a treatment in another jurisdiction.

Terminal and Life-Threatening Disease Mode

Therovia shall provide a specialized mode for serious, life-threatening, terminal, rapidly progressive, or treatment-resistant disease.

This mode may broaden treatment discovery to include:

Investigational therapies
Clinical trials
Expanded access
Compassionate use
Foreign-approved therapies
Off-label therapies
Experimental therapies
Emerging therapies
Treatment combinations
Precision medicine
Rare disease programs
Potentially curative approaches

The system shall clearly identify evidence limitations and access requirements.

Cure Classification

Therovia shall use strict definitions when describing cures.

A documented cure shall require appropriate supporting evidence.

The system shall distinguish cure from:

Remission
Long-term disease control
Symptom reduction
Temporary response
Disease stabilization
Preventive intervention
Experimental potential
Anecdotal claims

No treatment shall be labeled a cure solely because an organization, manufacturer, practitioner, publication, or user describes it as one.

Community Contributions

The system may support community contributions to treatment records, sources, corrections, translations, and jurisdictional information.

Community-submitted information shall be identified as such and shall pass appropriate validation processes before being classified as verified information.

Governance

Therovia governance shall define processes for:

Source inclusion
Source evaluation
Evidence classification
Treatment classification
Safety classification
Regulatory classification
Conflict resolution
Corrections
Retractions
Human review
AI-generated information
Community contributions
Data quality
Legal access information

All significant classification changes should remain auditable.

Mission Statement

Therovia: Because the World Has More Treatment Options.

Therovia is designed to expand treatment discovery beyond geographic, regulatory, and information boundaries while preserving the distinctions necessary for responsible medical information.

Its fundamental principle is:

Discover everything. Distinguish everything. Verify everything.

Specification Branding License (SBL)

Standard

Fully AGPL-3.0+ compliant system
Copyleft enforced for network deployments
Required attribution:

Roxanne Ardary
https://www.roxanneardary.com/

Optional

Specification Branding License (SBL)
Attribution-free commercial deployment
Pricing based on scale, usage, and deployment scope
https://roxanneardary.com/therovia/

License & Notice Requirements

Therovia is released under the GNU Affero General Public License v3.0 or later (AGPL-3.0+).

By contributing to any Open Arsenal project, you agree that your contributions will also be released under this license.

Please note the following:

All contributions must comply with the AGPL-3.0+ terms.
Under Section 7 of the license, all redistributions, forks, and derivative works must preserve attribution to Roxanne Ardary and roxanneardary.com.
Therovia specifications are free to use with attribution. A Specification Branding License can be negotiated upon request.
The project’s notice.md file tracks attribution requirements and contributor acknowledgments. Any update that adds new contributors or modifies attribution should also update notice.md.
When submitting a pull request, ensure that any new files maintain the attribution headers where applicable.
Network-deployed versions of this software must also remain fully AGPL-3.0+ compliant, including exposure of source code modifications when applicable under the license.

For full legal details, please refer to the AGPL-3.0+ license and the project’s notice.md file.

Notice – Therovia

Attribution Requirement: Under Section 7 of the AGPL 3.0+ license, all redistributions, forks, and derivative works, including network-deployed versions of this project, must provide attribution to Roxanne Ardary and roxanneardary.com.

Contributors

This file tracks contributors and their specific contributions to the project.

Roxanne Ardary, roxanneardary.com – August 23, 2026
Created the repository for Therovia. Created the specification for a global AI-powered treatment intelligence system that discovers and organizes treatment options, therapies, investigational treatments, clinical trials, and potential treatment access pathways from around the world.
[Add other contributors here] – [Date]
[Describe contribution in one sentence]

License – Therovia

This repository is licensed under the GNU Affero General Public License v3.0 or later (AGPL-3.0+).

Key Points

You are free to use, modify, and distribute the code.
All redistributions, forks, and derivative works or network-deployed versions must also be licensed under AGPL-3.0+ and provide attribution to Roxanne Ardary and roxanneardary.com as required under Section 7 of the license.
The software is provided “as is,” without warranty of any kind.

For the full license text, see GNU AGPL-3.0 License.